Argenx SE (ARGX)
| Market Cap | 15.88B |
| Revenue (ttm) | 44.42M |
| Net Income (ttm) | -645.03M |
| Shares Out | 51.31M |
| EPS (ttm) | -12.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $302.36 |
| Previous Close | $316.09 |
| Change ($) | -13.73 |
| Change (%) | -4.34% |
| Day's Open | 311.40 |
| Day's Range | 301.29 - 311.40 |
| Day's Volume | 139,566 |
| 52-Week Range | 212.66 - 382.15 |
July 22, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, toda...
July 14, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, toda...
Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvement s in strength and quality of life measures in g eneralized m yasthenia g ravis (gMG )
argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate.
Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting cusatuzumab. The pair first came together to develop th...
Regulated Information/Inside Information
June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today...
June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today...
Shares of argenx (NASDAQ:ARGX) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 60.68% year over year to ($0.81), which may not compare to the estimat...
Japanese Marketing Authorization Application (J-MAA) for efgartigimod accepted for review by Japan's Pharmaceuticals and Medical Device Agency (PMDA) for generalized myasthenia gravis (gMG)
argenx (NASDAQ:ARGX) releases its next round of earnings this Friday, May 14. Here is Benzinga's essential guide to argenx's Q1 earnings report.
May 1 1 , 20 2 1 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer...
May 7, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today ...
April 28, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, tod...
Shares of argenx (NASDAQ:ARGX) fell 3.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 60.08% year over year to ($4.21), which missed the es...
- Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG)
The FDA has accepted for review Argenx SE's (NASDAQ: ARGX) marketing application seeking approval for intravenous (IV) efgartigimod, for the treatment of generalized myasthenia gravis (gMG). Myasthenia ...
February 25, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, ...
Regulated information
Regulated information — Inside information
Regulated information — Inside information
-No observed elevation of cholesterol markers related to treatment with efgartigimod
Regulated information — Inside information
Regulated Information/Inside Information
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up...
Breda, the Netherlands – Jan. 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, to...
January 4, 2021 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseas...
November 23, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune dise...
BREDA, the Netherlands and GHENT, Belgium, Nov. 17, 2020 /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe au...
November 9, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disea...
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q3 2020 Results - Earnings Call Transcript
Shares of argenx (NASDAQ:ARGX) decreased 6.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 450.00% year over year to ($3.96), which missed ...
- Biologics License Application (BLA) for efgartigimod in generalized myasthenia gravis (gMG) on track to be submitted to U.S. Food and Drug Administration (FDA) by end of 2020 -
October 15, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disea...
Argenx: Competitive Positioning In The GMG Space
September 2, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune d...
August 4, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune dise...
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2020 Results - Earnings Call Transcript
July 30, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disea...
On Thursday, July 30, argenx (NASDAQ: ARGX) will release its latest earnings report.
argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Regulated information
Regulated information — Inside information
Regulated information — Inside information
argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.
Regulated information — Inside information
About ARGX
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indic... [Read more...]
| Industry Biotechnology | IPO Date May 18, 2017 |
| CEO Tim Van Hauwermeiren | Employees 336 |
| Stock Exchange NASDAQ | Ticker Symbol ARGX |
Financial Performance
In 2020, Argenx SE's revenue was 36.43 million, a decrease of -47.80% compared to the previous year's 69.78 million. Losses were -528.92 million, 224.6% more than in 2019.
Analyst Forecasts
According to 17 analysts, the average rating for Argenx SE stock is "Buy." The 12-month stock price forecast is 342.47, which is an increase of 13.27% from the latest price.